Bristol Lowers EPS Guidance On Plavix Decision

Bristol-Myers Squibb downgraded its full year eps guidance by up to 24% based on the impact of Apotex' launch of generic clopidogrel.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet